157 related articles for article (PubMed ID: 20359637)
1. Prognostic classification and risk assessment in myelodysplastic syndromes.
Cazzola M; Malcovati L
Hematol Oncol Clin North Am; 2010 Apr; 24(2):459-68. PubMed ID: 20359637
[TBL] [Abstract][Full Text] [Related]
2. Classification and prognostic evaluation of myelodysplastic syndromes.
Cazzola M; Della Porta MG; Travaglino E; Malcovati L
Semin Oncol; 2011 Oct; 38(5):627-34. PubMed ID: 21943669
[TBL] [Abstract][Full Text] [Related]
3. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS).
Malcovati L; Della Porta MG; Strupp C; Ambaglio I; Kuendgen A; Nachtkamp K; Travaglino E; Invernizzi R; Pascutto C; Lazzarino M; Germing U; Cazzola M
Haematologica; 2011 Oct; 96(10):1433-40. PubMed ID: 21659359
[TBL] [Abstract][Full Text] [Related]
4. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome.
Mills KI; Kohlmann A; Williams PM; Wieczorek L; Liu WM; Li R; Wei W; Bowen DT; Loeffler H; Hernandez JM; Hofmann WK; Haferlach T
Blood; 2009 Jul; 114(5):1063-72. PubMed ID: 19443663
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndromes classification and risk stratification.
Komrokji RS; Zhang L; Bennett JM
Hematol Oncol Clin North Am; 2010 Apr; 24(2):443-57. PubMed ID: 20359636
[TBL] [Abstract][Full Text] [Related]
6. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
Della Porta MG; Tuechler H; Malcovati L; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres MA; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D; Greenberg PL; Cazzola M
Leukemia; 2015 Jul; 29(7):1502-13. PubMed ID: 25721895
[TBL] [Abstract][Full Text] [Related]
7. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
8. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.
Malcovati L; Germing U; Kuendgen A; Della Porta MG; Pascutto C; Invernizzi R; Giagounidis A; Hildebrandt B; Bernasconi P; Knipp S; Strupp C; Lazzarino M; Aul C; Cazzola M
J Clin Oncol; 2007 Aug; 25(23):3503-10. PubMed ID: 17687155
[TBL] [Abstract][Full Text] [Related]
9. Impact of iron overload by transfusion on survival and leukemia transformation of myelodysplastic syndromes in a single center of China.
Wang Y; Huang L; Hua Y; Liu H; Jiang H; Wang H; Zhang W; Fu R; Shao Z
Hematology; 2021 Dec; 26(1):874-880. PubMed ID: 34753406
[TBL] [Abstract][Full Text] [Related]
10. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
[TBL] [Abstract][Full Text] [Related]
11. Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database.
Enrico A; Bestach Y; Flores MG; Arbelbide J; Serale C; Novoa V; Crisp R; Rivas MM; Larripa I; Belli C
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):743-752.e5. PubMed ID: 28797621
[TBL] [Abstract][Full Text] [Related]
12. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems.
Bektaş Ö; Üner A; Eliaçık E; Uz B; Işık A; Etgül S; Bozkurt S; Haznedaroğlu İC; Göker H; Sayınalp N; Aksu S; Demiroğlu H; Özcebe Oİ; Büyükaşık Y
Turk J Haematol; 2016 Jun; 33(2):119-26. PubMed ID: 26376664
[TBL] [Abstract][Full Text] [Related]
14. A prognostic score for patients with lower risk myelodysplastic syndrome.
Garcia-Manero G; Shan J; Faderl S; Cortes J; Ravandi F; Borthakur G; Wierda WG; Pierce S; Estey E; Liu J; Huang X; Kantarjian H
Leukemia; 2008 Mar; 22(3):538-43. PubMed ID: 18079733
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia.
Matsushima T; Handa H; Yokohama A; Nagasaki J; Koiso H; Kin Y; Tanaka Y; Sakura T; Tsukamoto N; Karasawa M; Itoh K; Hirabayashi H; Sawamura M; Shinonome S; Shimano S; Miyawaki S; Nojima Y; Murakami H
Blood; 2003 May; 101(9):3386-90. PubMed ID: 12506028
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic syndromes: diagnosis and staging.
Malcovati L; Nimer SD
Cancer Control; 2008 Oct; 15 Suppl():4-13. PubMed ID: 18813205
[TBL] [Abstract][Full Text] [Related]
17. [Myelodysplastic syndromes: preleukemic syndromes].
Tassin F; Hermanne JP; Schaaf-Lafontaine N; Herens C; Thiry A; Paulus JM; Boniver J; Fillet G
Rev Med Liege; 1998 Jun; 53(6):357-62. PubMed ID: 9713217
[TBL] [Abstract][Full Text] [Related]
18. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
19. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
Della Porta MG; Malcovati L; Strupp C; Ambaglio I; Kuendgen A; Zipperer E; Travaglino E; Invernizzi R; Pascutto C; Lazzarino M; Germing U; Cazzola M
Haematologica; 2011 Mar; 96(3):441-9. PubMed ID: 21134982
[TBL] [Abstract][Full Text] [Related]
20. The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes.
Castelli R; Schiavon R; Deliliers GL
Med Oncol; 2018 Feb; 35(3):33. PubMed ID: 29417235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
